Nanexa: Validation from Novo Nordisk positions Nanexa for an eventful year ahead - Emergers

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two additional evaluation agreements, investors have enjoyed a welcome rebound in the share price that has now more than doubled in the past three months. After the directed issue to Novo Nordisk, net cash stands at SEK 81m meaning that Nanexa is fully financed well into 2024. With the initiation of Phase I with NEX-22 in 2023 and initiation of Phase I with NEX-18 drifting into 2024, we see several potential triggers for a continued revaluation. Our rNPV calculation of the portfolio projects support a fair value of SEK 6.6-8.2 per share, with further upside as the company continues to de-risk the portfolio with progress in clinical development.

Länk till analysen i sin helhet: https://www.emergers.se/nanexa_k/

Länk till analysen i sin helhet: https://www.emergers.se/nanexa_l/